Avantor, Inc. Q2 FY2025 earnings call

• Leadership transition: Emmanuel Ligner appointed CEO effective August 18, Michael Stubblefield's final earnings call.
• Lab Solutions: Focus on retaining and growing share, with contract extensions with top pharma accounts (over $100M share gains), extension of contract with BIO Business Solutions. Digital initiatives like Avantor Navigator and pricing optimization.
• Bioscience Production: Bioprocessing fell short due to customer headwinds and manufacturing maintenance, but NuSil silicones grew low double digits.

Lab Solutions revenue was $1.122 billion, in line with expectations. Organically, it declined 1% year-over-year but grew 2% sequentially. Adjusted operating income was $133 million with an 11.9% margin. Bioscience Production revenue was $561 million, up 2% organically year-over-year and 7% sequentially. Bioprocessing was flat year-over-year due to headwinds, while Silicones grew low double digits. Adjusted operating income was $140 million with a 24.9% margin.

• Revised full-year organic revenue growth to negative 2% to flat from prior negative 1% to plus 1%.
• Adjusted EBITDA margin expected between 16.5% and 17%, adjusted EPS guidance $0.94-$0.98.
• Q3 organic revenue growth expected minus 4% to minus 2%, adjusted EBITDA margins low 16% range.

• Bioprocessing headwinds from customer challenges and manufacturing maintenance.
• Competitive intensity and pricing pressures impacting margins.
• FX impacts on euro-denominated debt affecting deleveraging.

Q: Vijay Kumar with Evercore asked about Q3 guidance and segment performance.

A: Brent Jones discussed segment ratable performance and seasonality in lab and bioprocessing.

Q: Michael Ryskin with Bank of America asked about bioprocessing long-term growth.

A: Michael Stubblefield talked about bioprocessing headwinds, customer challenges, and platform strength.

Q: Dan Brennan with TD Cowen asked about pricing environment and end market color.

A: Michael Stubblefield and Brent Jones discussed competitive intensity, price volume impact, and end market trends.

Q: Rachel Vatnsdal with JPMorgan asked about Lab Solutions guide and bioprocessing back orders.

A: Brent Jones discussed Lab Solutions guide prudence and bioprocessing back order resolution timeline.

Q: Luke Sergott with Barclays asked about sizing headwinds.

A: Michael Stubblefield discussed maintenance outage and customer headwind impacts.

Q: Tycho Peterson with Jefferies asked about free cash flow cut and lab margins.

A: Brent Jones and Michael Stubblefield discussed free cash flow related to rebates and lab margin path.

Q: Patrick Donnelly with Citi asked about bioprocessing order side and new CEO.

A: Michael Stubblefield talked about bioprocessing order side and Emmanuel Ligner's background.

Q: Doug Schenkel with Wolfe Research asked about VWR contract extensions and margins.

A: Michael Stubblefield and Brent Jones discussed VWR contract extensions, price impact on margins, and margin conviction.